title: Phospholipase A2 stimulates rat gastric epithelial cell line (RGM-1) migration.
abstract: OBJECTIVE
  The effect of phospholipase A2 (PLA2) and its phospholipid metabolites on gastric epithelial migration was examined using an in vitro wounding model of confluent monolayers of rat gastric epithelial cell line RGM-1.
  
  
  RESULTS
  Lysophosphatidylcholine (lysoPC) (0.01 100 ng/ml) as well as PLA2 (0.01-100 mU/ml) dose-dependently increased the cell migration. Lysophosphatidic acid (10 ng/ml) also increased the migration, but no significant increase in migration was observed when stimulated by lysophosphatidylethanolamine (10 ng/ml) or lysophosphatidylserine (10 ng/ml). Addition of 4-bromophenacyl bromide (BPB), a PLA2 inhibitor, completely blocked the effect of PLA2. However, addition of piroxicam (a cyclooxygenase inhibitor) or nordihydroguaiaretic acid (a lipoxygenase inhibitor) had no significant effect. Combination of PLA2 (10 mU/ml) with lysoPC (10 ng/ml) had no additive effect on migration. Moreover, lysoPC levels were increased in the cells after incubation with PLA2 (10 mU/ml). After pretreatment of RGM-1 cells with replication-inhibiting doses of mitomycin C. PLA2 and lysoPC still increased the cell migration.
  
  
  CONCLUSIONS
  These data suggest that PLA2 may, independently of proliferation, increase gastric epithelial migration mainly via lysoPC production.
authors.affiliation: Second Department of Internal Medicine, Osaka University Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Minami
authors.forename: H
authors.initials: H
authors.lastname: Tojo
authors.forename: S
authors.initials: S
authors.lastname: Zushi
authors.forename: Y
authors.initials: Y
authors.lastname: Shinomura
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuzawa
mesh_terms: D000098:Acetophenones / Q000494:pharmacology; D000818:Animals; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects* / Q000293:injuries; D008244:Lysophosphatidylcholines / Q000032:analysis; D008246:Lysophospholipids / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D054467:Phospholipases A2; D010894:Piroxicam / Q000494:pharmacology; D051381:Rats; D013268:Stimulation, Chemical
chemical_list: D000098:Acetophenones; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D008244:Lysophosphatidylcholines; D008246:Lysophospholipids; D010894:Piroxicam; C006065:We 201; D009637:Masoprocol; D010741:Phospholipases A; D054467:Phospholipases A2; C006821:4-bromophenacyl bromide